SETD2 mutations are quite common in ccRCC (7.4%–11.6%), pediatric high-grade glioma (HGG; 15%), and adult HGG (8%) (Cancer Genome Atlas Research Network, 2013; Dalgliesh et al., 2010; Duns et al., 2010; Fontebasso et al., 2013; Hakimi et al., 2013b; Varela et al., 2011). The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.